Sign in

    Chase Nicheboker

    Senior Equity Research Analyst at Craig-Hallum Capital Group

    Chase Knickerbocker is a Senior Equity Research Analyst at Craig-Hallum Capital Group, specializing in Specialty Pharmaceutical, Biotech, and Medical Technology companies. He has covered firms such as Adherex Technologies, PolyPid, DiaMedica Therapeutics, Butterfly Network, Indivior, and NeurAxis and has achieved a 58.7% success rate with an average return of 22.06% on his recommendations. Knickerbocker brings a commercial perspective to his equity research, having built his career at Craig-Hallum and focusing on healthcare since joining the firm. He holds relevant securities licenses and professional credentials, supporting his reputation for delivering actionable, well-performing investment insights.

    Chase Nicheboker's questions to MediWound (MDWD) leadership

    Chase Nicheboker's questions to MediWound (MDWD) leadership • Q2 2025

    Question

    Chase Nicheboker from Craig-Hallum Capital Group asked about the timeline for FDA feedback on the DFU trial, the status of VLU site activation and patient competition, and the potential impact of proposed reimbursement changes for skin substitutes on EscharEx utilization.

    Answer

    CEO Ofer Gonen confirmed they are approaching the FDA in H2 2025 for DFU protocol feedback and that most U.S. VLU sites are active, with European sites catching up. He sees minimal impact from competing CTP trials. EVP Barry Wolfferson opined that the proposed reimbursement changes, which require proper wound bed preparation, are a 'huge win' for EscharEx, positioning it as a critical precursor to CTP application.

    Ask Fintool Equity Research AI